These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 34047443)

  • 1. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.
    Tsapas A; Karagiannis T; Kakotrichi P; Avgerinos I; Mantsiou C; Tousinas G; Manolopoulos A; Liakos A; Malandris K; Matthews DR; Bekiari E
    Diabetes Obes Metab; 2021 Sep; 23(9):2116-2124. PubMed ID: 34047443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
    Kanters S; Wilkinson L; Vrazic H; Sharma R; Lopes S; Popoff E; Druyts E
    BMJ Open; 2019 Jul; 9(7):e023458. PubMed ID: 31340953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
    Sharma R; Wilkinson L; Vrazic H; Popoff E; Lopes S; Kanters S; Druyts E
    Curr Med Res Opin; 2018 Sep; 34(9):1595-1603. PubMed ID: 29764222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Tsapas A; Avgerinos I; Karagiannis T; Malandris K; Manolopoulos A; Andreadis P; Liakos A; Matthews DR; Bekiari E
    Ann Intern Med; 2020 Aug; 173(4):278-286. PubMed ID: 32598218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.
    Avgerinos I; Manolopoulos A; Michailidis T; Kitsios K; Liakos A; Karagiannis T; Dimitrakopoulos K; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2021 Mar; 23(3):822-831. PubMed ID: 33300282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.
    Avgerinos I; Michailidis T; Liakos A; Karagiannis T; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Mar; 22(3):335-345. PubMed ID: 31637820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
    Langford BE; Evans M; Haskins-Coulter T; O'Connor M; Cant HEO; Eddowes LA; Edmonds C; Tank A
    Diabetes Obes Metab; 2020 Jan; 22(1):39-50. PubMed ID: 31468649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.
    Ma H; Lin YH; Dai LZ; Lin CS; Huang Y; Liu SY
    BMJ Open; 2023 Mar; 13(3):e061807. PubMed ID: 36882248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.
    Wu S; He Y; Wu Y; Ji Y; Hou L; Liu X; Ge Y; Yu Y; Yu Y; Wei Y; Qian F; Luo Q; Feng Y; Feng Y; Wang J; Huo M; Li H; Xue F; Liu Y
    Front Endocrinol (Lausanne); 2022; 13():897776. PubMed ID: 36034458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
    Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
    Kim YJ; Hwang SD; Lim S
    Front Endocrinol (Lausanne); 2020; 11():553. PubMed ID: 32973680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
    Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
    Zhang YS; Zheng YD; Yuan Y; Chen SC; Xie BC
    Front Endocrinol (Lausanne); 2021; 12():735824. PubMed ID: 34721294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.
    Hu X; Yang Y; Hu X; Jia X; Liu H; Wei M; Lyu Z
    Diabetes Obes Metab; 2022 Feb; 24(2):228-238. PubMed ID: 34617381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of SGLT2i on 24-hour ambulatory blood pressure in patients with type 2 diabetes complicating hypertension: a meta-analysis].
    Tian L; Wang QY; Sun RM; Qi MM; Li YX; Gao X; Zhang LQ; Ma X; Shi H; Yu J; Bai F
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Oct; 49(10):1000-1011. PubMed ID: 34674438
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials.
    Shi FH; Li H; Shen L; Fu JJ; Ma J; Gu ZC; Lin HW
    Diabetes Obes Metab; 2021 Sep; 23(9):2125-2136. PubMed ID: 34048142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.